About me
Marc is passionate about building ventures in the life sciences. He is co-Founder and Managing Partner of the Montana Children’s Health, a venture capital fund managed by Ship2B Ventures, where he focuses on creating and scaling companies dedicated to children’s health and pediatric innovation.
He is also co-Founder and Advisor at Chasing Science and Manor House Partners, both early-stage venture builders operating between London and Barcelona. From the UK, Marc advises organisations such as Deep Science Ventures and Inside Out, and he is a Partner at Ship2B Ventures and Advisor at The Child Lens.
Most recently, Marc served as Co-Founder and CEO of Rejuveron Senescence Therapeutics AG, Ninevah Therapeutics Ltd, and Senolytic Therapeutics Inc. He has also acted as a Board Member or Strategic Advisor to numerous biotech and health technology companies, including Aptadel Therapeutics, Retinset Therapeutics, Gate2Brain, Dive Medical, Oniria Therapeutics, Nanobots Therapeutics, Beat Therapeutics, Cebiotex, Cyclomed, and GeneTether.
Previously, Marc was a founder and advisor at Tech & Business Innovation (TBI), an academic firm specialising in knowledge exchange and corporate–academic partnerships. He supported investments and strategic partnerships at Life Biosciences Inc. in Europe and has served as an advisor and board member for multiple international organisations.
Marc has played a key role in the design and implementation of Entrepreneurs-in-Residence programs at institutions such as IRB Barcelona. Between 2010 and 2012, he worked with Isis Innovations (University of Oxford) as an associate consultant in Spain and Latin America. Earlier, from 2007 to 2011, he was part of Endor, a Spanish nanomedicine company, where he served as R&D Director—leading the development of drug-delivery nanosystems for cancer therapy—and as Business Development Director, launching nanotechnology products for the cosmetics and textile markets.
He also has experience in the pharmaceutical industry through his work at Novartis and has collaborated with leading research institutions, including Cancer Research UK and Boston College.
Marc holds a DPhil in Biochemistry from the University of Oxford (2006) and completed the Program for Leadership Development (PLD) at Harvard Business School (2011). He also earned an M.Sc. in Chemical Engineering (2001) and a B.Sc. in Chemistry (2000) from IQS Barcelona
